8-K
filed March 24, 2025, 7:59 PM ET
ticker ERNA
CIK 0000748592
debt
confidence high
sentiment neutral
materiality 0.55
Eterna Therapeutics issues $750K promissory note to insider Charles Cherington at 5% due June 2025
Ernexa Therapeutics Inc.
- Issued $750,000 promissory note to Charles Cherington, who owns ~32% of ERNA shares.
- Note bears 5% annual interest, payable at maturity; default rate 7%.
- Matures on earliest of June 15, 2025, or when Eterna raises >$5M in equity/convertible debt.
- Cherington also holds a $1.5M note from March 11, 2025, making total insider debt $2.25M.
- Note includes customary events of default, cross-default >$50k, and bankruptcy clauses.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001641172-25-000300
- form_type
- 8-K
- ticker
- ERNA
- cik
- 0000748592
- company_name
- Ernexa Therapeutics Inc.
- filed_at
- 2025-03-24T23:59:59+00:00
- discovered_at
- 2026-05-14T18:03:06.261706+00:00
- generated_at
- 2026-05-24T07:30:21.852027+00:00
- sec_items
- ["1.01", "2.03", "9.01"]
- event_type
- debt
- sentiment
- neutral
- materiality_score
- 0.55
- calibrated_materiality_score
- 0.55
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001641172-25-000300
- json_url
- https://secwatch.observer/filing/0001641172-25-000300.json
- markdown_url
- https://secwatch.observer/filing/0001641172-25-000300.md
- text_url
- https://secwatch.observer/filing/0001641172-25-000300.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/748592/000164117225000300/0001641172-25-000300-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/748592/000164117225000300/form8-k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
NKGen Biotech, Inc.
NKGen Biotech secures $2.42M additional loan from AlpineBrook; conversion price $0.08
NKGen Biotech, Inc.
June 2, 2026, 5:20 PM ET
debt
Items 1.01, 2.03, 3.02, 9.01
same SEC item: 1.01, 2.03, 9.01
same event type: debt
similar materiality
Filing page
SEC filing
USFD
US Foods upsizes ABL facility to $2.5B and extends maturity to 2031
US Foods Holding Corp.
June 2, 2026, 4:58 PM ET
debt
Items 1.01, 2.03, 9.01
same SEC item: 1.01, 2.03, 9.01
same event type: debt
similar materiality
Filing page
SEC filing
HTZ
Hertz issues $1B asset-backed notes via HVF III at rates 5.09%-10.67%
HERTZ GLOBAL HOLDINGS, INC
June 2, 2026, 4:42 PM ET
debt
Items 1.01, 2.03, 9.01
same SEC item: 1.01, 2.03, 9.01
same event type: debt
similar materiality
Filing page
SEC filing
FLEX
Flex Ltd. enters $1.45B senior term loan facility; proceeds to refinance acquisition debt
FLEX LTD.
June 2, 2026, 4:05 PM ET
debt
Items 1.01, 2.03, 9.01
same SEC item: 1.01, 2.03, 9.01
same event type: debt
similar materiality
Filing page
SEC filing
KMT
Kennametal expands credit facilities: revolver to $850M, new $500M term loan
KENNAMETAL INC
June 2, 2026, 4:05 PM ET
debt
Items 1.01, 2.03, 9.01
same SEC item: 1.01, 2.03, 9.01
same event type: debt
similar materiality
Filing page
SEC filing
BTU
Peabody prices $250M convertible notes due 2031, repurchases $241.2M of 2028 notes
PEABODY ENERGY CORP
June 2, 2026, 10:17 AM ET
debt
Items 1.01, 2.03, 3.02, 9.01
same SEC item: 1.01, 2.03, 9.01
same event type: debt
similar materiality
Filing page
SEC filing
CBLO
C2 Blockchain raises $130K and up to $1.2M via convertible notes with heavy dilution
C2 Blockchain, Inc.
June 2, 2026, 10:08 AM ET
debt
Items 1.01, 2.03, 3.02, 9.01
same SEC item: 1.01, 2.03, 9.01
same event type: debt
similar materiality
Filing page
SEC filing
NWE
NorthWestern Energy subsidiary enters $225M secured term loan, repays revolver
NorthWestern Energy Group, Inc.
June 2, 2026, 7:22 AM ET
debt
Items 1.01, 2.03, 9.01
same SEC item: 1.01, 2.03, 9.01
same event type: debt
similar materiality
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.